Traditional strategies to overcome antigen escape have focused on the genetic redesign of CAR constructs, aiming to improve targeting breadth or affinity. These approaches, although innovative, are often hampered by their complexity, extended timelines, and high production costs, limiting their scalability and clinical applicability. Recognizing these limitations, researchers at the Institute of Process Engineering (IPE), Chinese Academy of Sciences, have pioneered a novel biomimetic platform that enhances CAR T cell therapeutic efficacy without necessitating further genetic modifications.

This breakthrough platform leverages the biomolecular interaction between ferritin—a naturally occurring iron storage protein—and CD71, a transferrin receptor highly expressed on both leukemia cells and autologous CAR T cells. Through meticulous optimization of solvent conditions and assembly parameters, the researchers engineered a ferritin aggregation cell engager (FACE), designed to self-assemble and function as a molecular bridge. FACE simultaneously binds CD71 on CAR T cells and leukemia cells, thereby reinforcing cellular conjugation and potentiating the immunological synapse critical for target recognition and cytotoxicity.

Extensive validation was performed across multiple preclinical models, including patient-derived xenografts (PDX) with diverse leukemia subtypes and refractory disease phenotypes. FACE-enhanced CAR T cells demonstrated therapeutic equivalence to conventional CAR T cells at only one-fifth the cellular dose, significantly reducing the severity of cytokine release syndrome, a common and life-threatening complication of CAR T therapy. Remarkably, in models harboring leukemia cells with antigen expression diminished to below 10% of baseline, FACE-CAR T cells maintained robust antileukemic activity, achieving 100% survival rates—a feat unattainable by standard CAR T approaches.

Further refinement saw the development of a drug-loaded iteration termed FACED, whereby therapeutic agents are encapsulated within the ferritin’s intrinsic cage-like structure. FACED-CAR T cells exhibited enhanced efficacy against high tumor burdens, including antigen-negative leukemia populations responsible for relapse, by combining targeted cell engagement with localized drug delivery. Such innovations suggest a new paradigm wherein biomolecular scaffolds can augment immunotherapy precision and potency.

The significance of these findings extends beyond their therapeutic impact. The FACE platform employs endogenous proteins and FDA-approved polymer derivatives, ensuring biocompatibility and safety. Its straightforward, scalable manufacturing process enables seamless integration within existing CAR T production workflows as a culture supplement, circumventing the need for additional genetic interventions. This adaptability facilitates rapid clinical translation and broad applicability across diverse hematologic malignancies.

Collaborative efforts with clinical partners at Zhujiang Hospital and the Institute of Hematology & Blood Diseases Hospital facilitated robust analyses of patient samples, confirming the ubiquitous overexpression of CD71 across leukemia variants. An AI-assisted predictive framework developed by the research team further enhances the platform’s translational potential by enabling precision forecasting of FACE-mediated therapeutic improvements, enabling patient-specific tailoring of treatment strategies.

The peer review community has heralded this work as a major advance in the field of adoptive T cell therapies. By directly addressing antigen heterogeneity and treatment resistance without additional genetic manipulation, the FACE approach promises to mitigate key barriers currently limiting CAR T cell efficacy. Its modularity and efficacy in resistant leukemia models position it as a transformative tool for improving patient outcomes.

In summary, this novel biomimetic platform represents a paradigm shift in CAR T therapy for leukemia. Through innovative molecular engineering of cell–cell interfaces and strategic drug delivery, it amplifies therapeutic avidity and circumvents antigen escape. Supported by rigorous in vivo and in vitro validation, this strategy holds substantial promise for improving remission durability in relapsed and refractory leukemia. The work exemplifies the power of integrating biomimicry with immunotherapy to devise clinically relevant and scalable solutions to complex oncological challenges.

As the field advances toward increasingly sophisticated cellular therapies, such biomaterial-based enhancements could usher in a new era of precision immunoengineering. By optimizing the spatial and functional dynamics of immune effector and target cells, researchers can unlock previously inaccessible therapeutic avenues, extending hope to patients confronting aggressive and otherwise intractable hematologic malignancies.

Subject of Research:
Not applicable

Article Title:
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias

News Publication Date:
9-Mar-2026

Web References:
http://dx.doi.org/10.1016/j.cell.2026.02.005

Image Credits:
LI Feng

Keywords:
Leukemia, Blood diseases, Blood cancer, Adoptive T cell therapy, Genetic engineering, Pharmaceuticals

At the forefront of leukemia research, City of Hope will present pivotal results from the Paradigm trial—a phase 2, randomized, multi-center study comparing the efficacy of azacitidine combined with venetoclax against conventional induction chemotherapy in newly diagnosed, fit adults suffering from acute myeloid leukemia (AML). This investigation delves into novel therapeutic regimens aiming to enhance treatment responses while minimizing toxicity profiles. Dr. Ibrahim Aldoss, a distinguished hematologist, leads these efforts to redefine AML management based on molecular and functional disease characteristics.

Another critical leukemia-related highlight involves CD19-directed chimeric antigen receptor (CAR) T cell therapy deployed as a definitive consolidation strategy in older adults diagnosed with B-cell acute lymphoblastic leukemia (b-ALL) in their first complete remission. This advanced immunotherapy modality has demonstrated safety and therapeutic durability in maintaining minimal residual disease (MRD) negativity, a key prognostic marker that correlates with long-term survival. The application of CAR T cells in this demographic represents a transformative approach overcoming limitations traditionally faced by the elderly in tolerating intensive chemotherapy.

In the realm of lymphoma, City of Hope researchers will share a significant three-year follow-up analysis from the S1826 study. This data corroborates the superior progression-free survival observed with the immune checkpoint inhibitor nivolumab combined with the chemotherapy backbone AVD, compared to the brentuximab vedotin-AVD regimen in advanced-stage classic Hodgkin lymphoma. Such findings highlight the potential of harnessing the immune system to enhance frontline cancer control while mitigating treatment-related adverse events. Dr. Alex Herrera, an expert in lymphoma therapeutics, will elucidate these findings and their implications for clinical practice.

Expanding beyond traditional targets, novel BAFF receptor (BAFFR)-CAR T cells, designated PMB-CT01, exhibit promising durable responses and manageable toxicity in patients with relapsed or refractory B-cell lymphomas, including those with prior failure of CD19-directed therapies or CD19-negative disease phenotypes. This advancement underscores the strategic diversification of antigen targets in CAR T cell therapy to circumvent antigen escape and resistance mechanisms intrinsic to B-cell malignancies, an area led by Dr. Elizabeth Budde.

Addressing mantle cell lymphoma, an interim phase II study evaluates the combination of glofitamab, lenalidomide, and venetoclax (GLOVe) in treatment-naïve high-risk patients. Early response and safety metrics post-stage 1 enrollment suggest enhanced therapeutic synergy leveraging an antibody-based bispecific approach alongside targeted agents. Such combination regimens aim to overcome the aggressive biology characterizing mantle cell lymphoma, as presented by Dr. Tycel Phillips.

City of Hope’s expertise extends to multiple myeloma, where research on the safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel), a BCMA-targeted CAR T cell therapy, addresses challenges inherent in relapsed or refractory disease settings. Dr. Azra Borogovac will present data emphasizing real-world applicability of cellular therapies manufactured under stringent quality parameters, illustrating the balance between regulatory stringency and urgent clinical need.

Transplantation medicine at City of Hope ventures into total marrow and lymphoid irradiation (TMLI) combined with fludarabine-melphalan conditioning for matched donor hematopoietic cell transplantation in older patients with relapsed/refractory hematologic disease. This innovative conditioning regimen offers a refined radiation dose distribution to optimize transplant efficacy and reduce off-target toxicity. Dr. Monzr M. Al Malki’s contributions in refining transplant conditioning protocols address the crucial need to expand transplant candidacy among older and comorbid populations.

Moreover, the institution is pioneering first-in-human trials involving allogeneic CD6-CAR regulatory T cells (tregs) to mitigate chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation. This cellular therapy harnesses immune modulation to restore tolerance and thymic homeostasis, marking a potentially paradigm-shifting approach to one of transplantation’s most formidable complications. Insights into a Toll-like receptor 4 (TLR4) and heat shock protein 70 (HSP70) efferocytic program in thymic macrophages further elucidate mechanisms sustaining thymic output and immune reconstitution, as studied by City of Hope scientists.

Apart from scientific presentations, City of Hope is spearheading educational initiatives critical for disseminating cutting-edge knowledge. The 14th Annual BMT & Cell Therapy Winter Workshop, co-chaired by Dr. Marcel van den Brink, embodies a comprehensive platform addressing emergent themes in cellular therapies and transplantation. Additional symposia explore the latest standards in B-ALL treatment employing off-the-shelf bispecific antibodies and integrate functional with genomic precision medicine in blood cancers, facilitating a multidisciplinary treatment strategy.

A notable scientific workshop led by Dr. Pamela Becker focuses on the integration of functional assays and genomic data, propelling personalized hematologic malignancy therapies from bench to bedside. This synthesis of molecular insights and clinical phenotypes is essential for tailoring interventions that optimize efficacy and curtail resistance. Concurrently, Dr. van den Brink presents novel intersections between the microbiome, diet, and cancer immunotherapy, unveiling how host-environment interactions influence therapeutic outcomes.

In tackling infectious complications post-cellular therapies, educational spotlights led by Dr. Randy Taplitz delineate measures to reduce infection risks in immunocompromised patients. These guidelines are paramount to improving survival and quality of life, given the vulnerability induced by immune ablative treatments and prolonged cytopenias. City of Hope’s multifaceted approach encompasses not only therapeutic innovation but also comprehensive patient care paradigms.

Collectively, City of Hope’s robust presence at ASH 2025 illustrates a commitment to advancing hematology through translational research, precision medicine, and educational leadership. Their integrated model of innovative clinical trials, cutting-edge cellular therapy development, and rigorous biological discovery is setting new benchmarks in blood cancer treatment worldwide. This synthesis of expertise and technology promises to reshape therapeutic landscapes and deliver hope to patients battling some of the most challenging malignancies.

Subject of Research: Hematologic malignancies including leukemia, lymphoma, multiple myeloma, and transplantation therapies.

Article Title: City of Hope Unveils Transformative Advances in Blood Cancer Therapies at ASH 2025

News Publication Date: December 2024

Web References:
https://www.cityofhope.org/about-city-of-hope/leadership-team/marcel-van-den-brink
https://submit.hematology.org/program/session/117545
https://www.cityofhope.org/patients/find-a-doctor/ibrahim-aldoss
https://www.cityofhope.org/patients/find-a-doctor/alex-herrera
https://www.cityofhope.org/patients/find-a-doctor/elizabeth-budde
https://www.cityofhope.org/patients/find-a-doctor/tycel-phillips
https://www.cityofhope.org/patients/find-a-doctor/lindsey-murphy
https://www.cityofhope.org/patients/find-a-doctor/azra-borogovac
https://www.cityofhope.org/patients/find-a-doctor/monzr-al-malki
https://www.cityofhope.org/patients/find-a-doctor/amandeep-salhotra
https://www.cityofhope.org/patients/find-a-doctor/pamela-becker
https://www.cityofhope.org/patients/find-a-doctor/randy-taplitz

Keywords: Hematology, Blood cancer, Leukemia, Lymphoma, Multiple myeloma, Cancer immunology, Cellular therapies, CAR T cell therapy, Hematopoietic cell transplantation, Precision medicine, Immunotherapy, Graft-versus-host disease

The intricate landscape of leukemia research has long sought innovative approaches to circumvent the limitations of conventional chemotherapy, which often results in systemic toxicity and the emergence of drug resistance. Exosomes, nano-sized vesicles secreted by cells, have surged to the forefront as natural intercellular communication vehicles capable of transferring proteins, lipids, and nucleic acids. These vesicles can modulate recipient cell behavior, and harnessing their innate bioactive cargo offers a refined approach to cancer therapy.

Karimian and colleagues focused their investigation on BM-MSC-derived exosomes due to their inherent immunomodulatory properties and ability to home to tumor microenvironments. The study elucidates how these exosomes deliver regulatory molecules that specifically attenuate the expression of TUG1—a lncRNA implicated in the progression and chemoresistance of acute myeloid leukemia and other malignancies.

TUG1 has emerged as a critical player in oncogenesis, acting through multiple signaling pathways to promote cell proliferation, inhibit apoptosis, and facilitate leukemia cell survival. By targeting TUG1, BM-MSC exosomes initiate a cascade of molecular events that disrupt leukemia cell viability and proliferation. The modulation of TUG1 expression downregulates oncogenic pathways, potentially reversing the malignant phenotype of leukemic cells.

The researchers employed a robust array of molecular biology techniques to validate their findings, including quantitative real-time PCR to assess TUG1 expression levels, cell viability assays, and flow cytometry to determine apoptosis rates in THP-1 cells. The treated cell populations demonstrated significant reductions in TUG1 transcripts alongside marked increases in apoptotic markers, underscoring the exosomes’ efficacy in inducing leukemia cell death.

An intriguing aspect of this study is the demonstration that BM-MSC-derived exosomes can modulate lncRNA expression without genetic modification of the recipient cells. This suggests a non-invasive, biologically harmonious method of gene regulation, circumventing the risks associated with direct nucleic acid therapies such as viral vector delivery or synthetic oligonucleotides, which often face challenges of delivery efficiency and off-target effects.

Moreover, the study highlights the multifunctional nature of exosomes, which carry a diverse molecular cargo. The investigators speculate that components within the exosomes, including microRNAs and specific RNA-binding proteins, may be orchestrating the downregulation of TUG1. Future research will need to dissect the precise molecular constituents responsible for this modulation, offering opportunities for designing engineered exosomes with enhanced therapeutic payloads.

The implications of these findings extend beyond leukemia alone. The lncRNA TUG1 has been implicated in various cancers, suggesting that BM-MSC-derived exosomes could have a broader utility in oncology as modulators of aberrant lncRNAs. This broad-spectrum potential invites optimism for developing exosome-based therapies targeting malignancies with similarly dysregulated non-coding RNAs.

However, clinical translation remains a formidable challenge. The scalability of exosome production, stability in circulation, targeted delivery, and avoidance of immune clearance are critical parameters that must be optimized. Karimian et al.’s work significantly contributes to understanding the mechanistic foundations but also sets the stage for translational research to refine exosome-based therapeutics.

From a mechanistic standpoint, the study delves into how TUG1 influences leukemogenesis through downstream effectors. Evidence suggests TUG1 interacts with chromatin remodeling complexes, modulates miRNA availability, and affects key signaling pathways such as PI3K/AKT and Wnt/β-catenin, all of which contribute to leukemia cell survival and proliferation. By lowering TUG1 levels, BM-MSC exosomes destabilize these pathways.

The therapeutic potential is further reinforced by the observation that exosome treatment did not induce significant cytotoxicity in normal hematopoietic stem cells, indicating a degree of selectivity for malignant cells. This specificity enhances the appeal of exosome-based approaches, potentially reducing collateral damage to healthy tissues often seen in traditional chemotherapy.

Intriguingly, the study opens avenues for combinatorial therapies. BM-MSC exosomes could be integrated with existing chemotherapeutic regimes to potentiate drug sensitivity and overcome resistance mechanisms mediated by lncRNAs. This multipronged approach could improve overall patient outcomes by lowering treatment doses and mitigating side effects.

Furthermore, the immunomodulatory properties of BM-MSC exosomes may contribute to altering the tumor microenvironment, fostering anti-leukemic immune responses. The crosstalk between leukemia cells and their microenvironment underlies disease progression and therapy resistance, thus exosome-mediated interference could disrupt these pathogenic interactions.

The findings bring to light the dynamic role of extracellular vesicles in cancer biology, not merely as biomarkers but as active therapeutic agents capable of fine-tuning complex gene regulatory networks. This elevates our understanding of cell–cell communication in oncogenesis and paves the way to harness the full therapeutic potential of naturally occurring biological nanoparticles.

In conclusion, the study by Karimian and colleagues powerfully demonstrates that BM-MSC-derived exosomes can downregulate the oncogenic lncRNA TUG1 in THP-1 leukemia cells, inducing apoptosis and thwarting malignant progression. This innovative approach offers a novel, biologically inspired modality that could revolutionize leukemia treatment and potentially other malignancies characterized by dysregulated non-coding RNAs. Continued exploration of exosome biology and engineering will be paramount to translating these promising in vitro results into clinical reality, setting a new frontier in precision oncology.

Subject of Research:
The study investigates the role of bone marrow-derived mesenchymal stem cell (BM-MSC) exosomes in modulating the expression of the oncogenic long non-coding RNA TUG1 and their anti-leukemic effects on THP-1 human monocytic leukemia cells.

Article Title:
The potential role of BM-MSC-derived exosomes in TUG1 modulation: antileukemic effects on THP-1 cells.

Article References:
Karimian, F., Loghmani, Z., Vazifeh Shiran, N. et al. The potential role of BM-MSC-derived exosomes in TUG1 modulation: antileukemic effects on THP-1 cells. Med Oncol 42, 544 (2025). https://doi.org/10.1007/s12032-025-03103-7

Image Credits: AI Generated

DOI:
https://doi.org/10.1007/s12032-025-03103-7

Leukemia remains a formidable challenge in oncology, characterized by an overproduction of dysfunctional white blood cells. The aberrant activity of the BCL-2 protein is a well-documented factor contributing to the survival of these malignant cells, making it an attractive target for therapeutic interventions. This study’s authors have meticulously delved into natural compounds using an integrated virtual screening approach, which combines computational methods to predict the efficacy of various substances in modulating BCL-2 activity. By simulating molecular interactions, they aim to identify those natural compounds capable of binding to and inhibiting BCL-2.

The significance of utilizing natural compounds cannot be overstated. With increasing concerns about the side effects associated with synthetic drugs, there is a notable shift towards exploring the potential of phytochemicals and other bioactive substances derived from nature. By harnessing these compounds, researchers hope to uncover effective yet less toxic alternatives for leukemia treatment. The integration of virtual screening with natural product libraries opens a new frontier in pharmacology, allowing scientists to efficiently search for candidates that can specifically target the structures of proteins like BCL-2.

In their research, the team utilized a systematic virtual screening methodology that included multiple stages. Initially, they compiled a diverse library of phytochemicals optimized for their potential activity against BCL-2. Following this, they employed docking simulations to evaluate how well these compounds could fit into the BCL-2 binding site. This computational approach not only accelerated the screening process but also provided valuable insights into the molecular characteristics that could enhance binding affinity and specificity.

Among the many compounds analyzed, the results indicated several candidates with promising inhibitory potential. The study provides an extensive discussion on the mechanisms of action for these natural inhibitors, detailing how they could disrupt the anti-apoptotic functions of BCL-2 and promote programmed cell death in leukemic cells. This finding is particularly encouraging, as the ability to induce apoptosis in cancer cells is a primary goal in therapeutic interventions for leukemia.

The implications of discovering new BCL-2 inhibitors extend beyond the mere identification of potential drug candidates. The research team discusses the broader context of their findings, emphasizing how these natural compounds could serve as lead molecules for further development. With additional studies, these inhibitors might undergo modifications to enhance their drug-like properties, leading to the eventual formulation of new therapies approved for clinical use.

In addition to the promising results, the authors acknowledge the inherent challenges associated with translating these findings into clinical applications. While virtual screening can efficiently identify potential inhibitors, the steps that follow—including validation through in vitro and in vivo studies—are critical in establishing the real-world effectiveness and safety profiles of these compounds. The pathway from laboratory discovery to clinical efficacy remains complex, with each proposed treatment needing rigorous testing to identify potential adverse effects and confirm therapeutic benefits.

Furthermore, the study delves into the significance of collaboration across disciplines in advancing cancer research. The integration of computational biology, medicinal chemistry, and clinical expertise is essential in navigating the complexities of developing new treatments for leukemia. The authors encourage ongoing interdisciplinary cooperation, highlighting that breakthroughs in drug discovery often arise from the confluence of diverse fields of science.

As researchers continue to push the boundaries of knowledge in pharmacology, this study represents a step forward in our understanding of leukemia therapeutics. The potential of natural products, combined with cutting-edge scientific methods, may lead to the next generation of cancer treatments. With each advancement, the hope of providing better, more effective therapies for patients suffering from leukemia becomes increasingly tangible.

Overall, the study underscores not only the importance of BCL-2 as a target in leukemia treatment but also the promising role of natural compounds in pharmaceutical innovation. As the research community continues to explore these avenues, patients may soon benefit from novel therapies tailored to their specific cancer biology, ultimately improving survival rates and quality of life.

By broadening the scope of research to include natural products, the scientific community stands to benefit greatly. The potential to discover new, effective inhibitors is not limited to BCL-2; similar methodologies could be applied to other oncogenic proteins and related pathways, expanding the arsenal available in the battle against cancer. The ongoing efforts in this area reflect a commitment to advancing healthcare while minimizing adverse effects, a goal shared by researchers and clinicians alike.

As we look to the future, this research serves as a reminder of the untapped wealth of knowledge inherent in natural products. Continued investigations into these compounds may yield transformative therapies that change the landscape of leukemia treatment, offering renewed hope to patients worldwide. As the study by Das, Mukherjee, and Mukunthan demonstrates, the pursuit of progress in cancer research is both an ongoing challenge and an exciting opportunity.

The path from scientific discovery to clinical application is often fraught with obstacles, yet the enthusiasm and dedication exhibited by researchers in this field signal a bright future. As new inhibitors of BCL-2 are explored, the potential impact on the landscape of leukemia treatment could be profound. Better understanding of these mechanisms and continued innovation in drug discovery methods may usher in an era of personalized medicine, where treatments are tailored to individual patient needs, optimizing outcomes and reducing side effects.

In conclusion, the ongoing evolution of cancer therapeutics is characterized by a commitment to leveraging the natural world in the search for effective treatments. As the findings of this recent study illustrate, the exploration of natural compounds through advanced screening methods not only holds promise for discovering potent BCL-2 inhibitors for leukemia but also serves as a model for future oncological research. The fight against cancer persists, and with each innovative approach, we draw closer to uncovering effective solutions that can improve patient lives and achieve better prognoses.

Subject of Research: Identification of natural BCL-2 inhibitors for leukemia.

Article Title: Identification of potential natural BCL-2 inhibitors for leukemia through an integrated virtual screening approach.

Article References: Das, U., Mukherjee, A., Mukunthan, K.S. et al. Identification of potential natural BCL-2 inhibitors for leukemia through an integrated virtual screening approach. BMC Pharmacol Toxicol 26, 176 (2025). https://doi.org/10.1186/s40360-025-01005-y

Image Credits: AI Generated

DOI: 10.1186/s40360-025-01005-y

Keywords: BCL-2, leukemia, natural inhibitors, virtual screening, cancer therapeutics, apoptosis, drug discovery, phytochemicals.

The concept of mining fungi for medicinal compounds is not new—antibiotics like penicillin owe their origins to fungal metabolites—but the curative promise of RiPPs in fungi has remained largely untapped until now. Fungal RiPPs present a unique biosynthetic challenge due to their complex synthesis pathways, distinctly different from the well-studied bacterial counterparts. These peptides are synthesized directly by ribosomes before undergoing intricate post-translational modifications that bestow them with enhanced pharmaceutical properties. The rarity and difficulty in purifying these molecules have historically hampered their integration into drug discovery, yet the meticulous work by this research team breaks new ground by uncovering a previously unknown assembly of RiPPs, termed asperigimycins, characterized by their exceptional heptacyclic benzofuranoindoline frameworks.

A. flavus, apart from its historical notoriety, harbors gene clusters previously elusive to researchers. Employing a combined approach of gene knockout experiments and mass spectrometry-based metabolic profiling, the team deciphered the genetic underpinnings responsible for RiPP biosynthesis in the fungus. This strategy allowed them to conclusively link specific proteins to the production of bioactive asperigimycins, while demonstrating that disabling these genes eradicated the signature chemical markers of these compounds in fungal cultures. Such integration of genetic and metabolomic data not only illuminated fungal RiPP biosynthesis but also set a methodological precedent for identifying novel natural products across other pathogenic or symbiotic fungi.

The purified asperigimycins exhibited remarkable anticancer activity in vitro, focusing primarily on leukemia cell lines. Two of the four distinct asperigimycin variants revealed significant cytotoxic effects without any chemical modification, underscoring their potential as lead compounds in drug development. Intriguingly, one variant modified with a lipid moiety analogous to components found in royal jelly—a nutrient-rich secretion essential for bee larvae development—demonstrated comparable efficacy to cytarabine and daunorubicin, both cornerstone drugs in leukemia treatment. This lipid conjugation not only increased potency but also highlighted a novel avenue to enhance cellular uptake and bioavailability of cyclic peptides, traditionally hindered by their large, complex structures.

Delving deeper into the mechanisms governing cellular entry, the researchers pinpointed a gene named SLC46A3 within leukemia cells that plays a pivotal role in facilitating the transport of asperigimycins from lysosomal compartments into the cytosol. This transporter’s gating function appears critical for the compounds’ therapeutic effects, suggesting that lipid modification may optimize the interaction with SLC46A3, thereby amplifying intracellular concentrations of the bioactive molecules. This insight unveils a new paradigm in drug design where modifying natural product structures to exploit endogenous trafficking pathways could revolutionize the delivery efficiency of cyclic peptide-based drugs.

Further mechanistic investigations revealed that asperigimycins exert their anticancer effects through disruption of microtubule dynamics, an essential process for mitotic cell division. By binding to components involved in microtubule polymerization, these fungal RiPPs selectively inhibit the proliferation of leukemia cells, sparing other cancer types and non-cancerous cells alike. This specificity is a breakthrough in targeted therapy, minimizing off-target effects and toxicity—a significant challenge with existing chemotherapy agents. Such precision medicine, built on natural product scaffolds, promises to enhance patient outcomes while reducing side effects.

Another compelling aspect of this discovery is the fungus’s restriction of asperigimycins’ activity spectrum, which includes no observed antibacterial or antifungal effects. This delineation hints at a sophisticated biological interaction, where these molecules have evolved to target specific eukaryotic cellular pathways, possibly as a defense mechanism in natural environments. Understanding this evolutionary context enriches drug discovery by providing clues on molecular specificity and guiding structural modification strategies to fine-tune pharmacological targets.

The potential ripple effects of this study extend beyond A. flavus. The team identified analogous gene clusters across various fungal species, implying a vast, untapped reservoir of RiPPs with diverse bioactive profiles awaiting exploration. Given the emerging significance of cyclic peptides in pharmaceutical pipelines—nearly two dozen have achieved clinical approval since 2000—this fungal RiPP frontier represents a propitious field for next-generation therapeutics. Exploiting fungal biodiversity could dramatically expand the chemical space accessible for drug design, inspiring multidisciplinary collaborations across synthetic biology, medicinal chemistry, and oncology.

The researchers stress that their next milestones involve in vivo testing of asperigimycins to evaluate pharmacokinetics, bioavailability, and safety profiles within animal models. Success in these stages could pave the path towards human clinical trials and eventual incorporation into cancer treatment regimens. Concurrently, the deeper understanding of transport genes like SLC46A3 opens avenues for companion diagnostics, allowing the identification of patient subsets most likely to benefit from RiPP-based therapies, fostering personalized medicine.

As this research exemplifies the creative potential of revisiting long-dreaded microorganisms, it underscores nature’s enduring capacity to inspire innovative solutions to complex diseases. The transformation of Aspergillus flavus from an agent of historical calamity into a beacon of therapeutic hope highlights how integrative science—melding molecular biology, chemical engineering, and pharmacology—can turn ancient microbial curses into modern cures. In the words of Professor Sherry Gao, “Nature has given us this incredible pharmacy. It’s up to us to uncover its secrets.”

This pioneering work was accomplished through a collaborative effort incorporating institutions including the University of Pennsylvania School of Engineering and Applied Science, Rice University, the University of Pittsburgh, MD Anderson Cancer Center, Washington University School of Medicine, Baylor College of Medicine, and the University of Porto. Supported by a spectrum of federal and private funding bodies, the research advances not only scientific understanding but also intellectual property, with a provisional patent application filed to safeguard the novel chemical entities discovered.

As researchers continue to harness fungal RiPPs’ unexplored diversity, the implications for cancer therapy, and potentially other disease areas, become profound. This breakthrough invites the scientific community to revisit and rethink natural product-based drug discovery, especially in underexplored domains harboring biologically unprecedented molecules. The advent of asperigimycins symbolizes a leap forward, offering hope for more efficient, targeted, and less toxic cancer treatments crafted in the crucible of fungal biochemistry.

Subject of Research: Cells

Article Title: A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities

News Publication Date: 23-Jun-2025

Web References:
https://www.nature.com/articles/s41589-025-01946-9

References:
Based on the results presented herein, a provisional patent application (RICE.P0154US.P1) has been filed through Rice University.

Image Credits: Bella Ciervo

Keywords

Aspergillus flavus, fungal RiPPs, asperigimycins, cancer therapy, leukemia, cyclic peptides, ribosomally synthesized peptides, post-translational modifications, microtubule inhibition, SLC46A3, natural products, drug discovery

At the core of this research lies the elegant biology of stem cells, which possess the remarkable ability to differentiate into various specialized cell types, governed by tightly regulated genetic programs. The team’s challenge was to decode the complex genetic instructions that prompt a stem cell to commit specifically to a blood lineage. To tackle this, Dr. Bigas’ lab performed an unbiased, genome-wide screen in the murine model, systematically testing thousands of genes to identify those responsible for steering embryonic stem cells toward becoming hematopoietic progenitors. Their perseverance paid off when they uncovered a combination of seven critical genes that, when activated in a precise temporal manner, successfully reprogrammed mouse embryonic stem cells into HSPCs.

These newly induced HSPCs were not only phenotypically similar to natural blood stem cells but also demonstrated functional competence in vivo, as they engrafted in adult mice and regenerated a fully operational hematopoietic system. This system included the production of diverse blood cell lineages essential for immune defense, oxygen transport, and clotting. The functional validation of these lab-generated cells marks an essential milestone, proving that targeted gene activation can recapitulate the complexity of blood stem cell development, a feat that opens new therapeutic avenues.

Critically, the implications extend beyond mouse models. Dr. Bigas emphasizes the evolutionary conservation of these genes, noting their high sequence similarity across species, including humans. This conservation underpins the hypothesis that the mechanisms controlling stem cell fate and differentiation are fundamentally shared, suggesting that the mammalian blueprint revealed by this study could be applicable in human systems. Current efforts are underway to translate these findings to human embryonic stem cells, an essential step toward clinical application.

This breakthrough is part of a larger ERC synergy-funded initiative titled "Making Blood," which aspires to establish a cutting-edge platform capable of manufacturing human HSPCs on demand. Should this endeavor succeed, it could herald a new era in the treatment of blood-related disorders, where patients no longer require compatible donors for bone marrow transplantation—a procedure that often involves significant logistical and immunological challenges.

The research, recently published in the esteemed journal Blood, sheds light on the intricate gene regulatory networks that define hematopoietic fate decisions. By employing an unbiased genome-wide approach rather than relying on candidate gene trials, the team ensured a comprehensive and objective discovery process. Such thoroughness enhances the robustness of the findings and offers an expanded genetic toolkit for synthetic biology approaches aimed at blood regeneration.

Importantly, the study integrates developmental biology with translational medicine. Collaborations with experts in pediatric and developmental leukemia, Dr. Clara Bueno and Dr. Pablo Menéndez, have contextualized the importance of these genes in human disease, reinforcing the potential for targeted genetic manipulation to correct hematopoietic deficiencies or malignancies born from aberrant stem cell differentiation.

The potential of producing HSPCs ex vivo with precise genetic programming holds transformative promise for regenerative therapies, immune system reconstitution, and personalized medicine. It challenges current paradigms in transplantation biology, where matching donor and recipient immune profiles remains a critical barrier. By generating stem cells that can be tailored to individual patient needs, this technology could circumvent issues of compatibility and graft-versus-host disease.

The pathway forward, however, is complex. Translating murine genetic programs to human stem cells requires meticulous validation of gene function, timing, and expression levels, as minor deviations may result in incomplete or aberrant differentiation. Additionally, ensuring the safety and stability of genetically reprogrammed cells before clinical use is paramount, requiring comprehensive preclinical studies and regulatory scrutiny.

This work also highlights the synergistic power of interdisciplinary research centers such as the Josep Carreras Leukaemia Research Institute and the Hospital del Mar Research Institute, both recognized for excellence in biomedical science and translational research. Their combined expertise in hematology, oncology, stem cell biology, and clinical research facilitates rapid movement from bench to bedside, accelerating the development of novel therapies.

Funding from national and European scientific bodies, along with prestigious foundations, underscores the strategic importance placed on regenerative medicine for hematological disorders. Investment into projects like “Making Blood” reflects a broader commitment to harnessing the full potential of stem cells to address unmet clinical needs, including leukemia, anemia, and immunodeficiencies.

As research progresses, the scientific community remains vigilant but optimistic. Dr. Bigas’ group continues to unravel the complex genetic landscapes governing stem cell fate, poised to unlock further biological secrets and deliver therapeutic breakthroughs. Their work stands at the nexus of molecular biology, genetics, and clinical innovation, capturing imaginations and catalyzing hope among patients and researchers alike.

This landmark discovery revives the vision of producing a renewable source of healthy blood stem cells, potentially reshaping the management of hematological diseases. It paves the way for future innovations where laboratory-engineered cells could replace damaged or diseased marrow, offering cures where none existed before. The era of regenerative hematology may soon move from conceptual ambition to clinical reality.

Subject of Research: Cells

Article Title: An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells

News Publication Date: 10-Apr-2025

Web References:

• Blood Journal Article
• Josep Carreras Leukaemia Research Institute
• Bigas Lab Stem Cells and Cancer Research

References:
Luis Galan Palma, Gayathri M Kartha, Maria Maqueda, Mercedes Barrero, Eric Canton, Arnau Iglesias, Jessica Gonzalez Miranda, Patricia Herrero Molinero, Raul Torres-Ruíz, Bernhard Payer, Clara Bueno, Pablo Menendez, Lluis Espinosa, Anna Bigas; An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells. Blood 2025; blood.2024027742. doi: 10.1182/blood.2024027742

Image Credits: Credit: Hospital del Mar Research Institute

Keywords: Stem cells, Blood cells, Bone marrow cells, Bone marrow

One of the most illuminating studies involved constructing an exhaustive spatial atlas detailing the progression of pancreatic cancer metastases. Pancreatic cancer, a notoriously aggressive malignancy with a five-year survival rate lingering near 12%, poses significant treatment hurdles largely due to its metastatic tendencies soon after diagnosis. Led by Drs. Linghua Wang and Anirban Maitra, researchers meticulously analyzed 55 tumor samples from 13 patients using high-resolution spatial mapping techniques. By tracking clonal evolution and delineating cancer cell states alongside tumor microenvironment dynamics, the team uncovered pivotal lineage shifts as cancer cells transitioned from the pancreas to distant organs. This detailed landscape exposed two discrete epithelial phenotypes characterized by unique transcriptomic signatures, each bearing distinct prognostic value. This revelation underscores the urgent need to incorporate cellular heterogeneity and microenvironmental context when pinpointing biomarkers and crafting targeted therapies for this treatment-resistant cancer.

Turning attention to lung cancer, researchers harnessed imaging mass cytometry to chart immune landscape changes within lung precancers and tumors. Given that lung cancer is frequently diagnosed at advanced stages, understanding its earliest immunological shifts is vital for interception strategies. Investigators led by Bo Zhu and Jia Wu examined 114 lung tissue samples to explore the transition from innate to adaptive immunity during disease progression. Their analysis revealed an intriguing pattern involving TIM-3, an immune checkpoint receptor. TIM-3 expression was elevated at precancerous stages but diminished as lesions advanced to invasive cancer. Functional studies demonstrated that blocking TIM-3 during precancer stages significantly curtailed tumor growth, offering compelling evidence for TIM-3 as a highly promising target for early immunotherapeutic intervention in lung cancer.

In mantle cell lymphoma (MCL), an aggressive B-cell malignancy historically resistant to curative treatments, novel therapeutic combinations have emerged from Phase III clinical trials. Under the leadership of Michael Wang, the ECHO trial evaluated the addition of acalabrutinib, a highly selective second-generation Bruton’s tyrosine kinase inhibitor, to the standard regimen. This large-scale study, encompassing 598 patients, revealed a striking improvement in median progression-free survival (PFS)—extending from 49.6 months in the placebo arm to 66.4 months in the acalabrutinib cohort. The favorable safety profile and efficacy outcomes have catalyzed the U.S. Food and Drug Administration’s approval of this combination as the new frontline standard, particularly benefiting older patients newly diagnosed with MCL.

Addressing the complexities of acute myeloid leukemia (AML), investigators led by Michael Andreeff and Yuki Nishida explored the manipulation of leukemia stem/progenitor cells (LSPCs), which notoriously evade chemotherapy by residing in dormant states within the bone marrow niche. Their study focused on valemetostat, a dual inhibitor targeting epigenetic regulators EZH1 and EZH2, proteins implicated in maintaining stem cell quiescence. Rather than directly inducing cytotoxicity, valemetostat disrupts the dormancy of malignant LSPCs, effectively “waking” these cells and rendering them susceptible to conventional chemotherapy such as cytarabine. Preclinical findings demonstrated enhanced leukemic cell eradication and improved survival outcomes without damaging normal hematopoietic stem cells. This selective targeting approach could revolutionize AML therapy by overcoming a critical mechanism of drug resistance.

Glioblastoma, the most prevalent and lethal form of primary brain tumor, continues to challenge clinicians due to its resistance to immune checkpoint blockade. A novel Phase I/II trial spearheaded by Shiao-Pei Weathers evaluated the integration of atezolizumab—an immune checkpoint inhibitor—with temozolomide chemotherapy and radiation therapy in patients with newly diagnosed disease. Although overall survival rates mirrored existing treatment paradigms, the study uncovered immune-enriched tumor microenvironments correlating with improved patient outcomes. Specifically, the mesenchymal subtype of glioblastoma exhibited heightened immune activity, suggesting intrinsic biological heterogeneity influences therapeutic response. In a surprising intersection of oncology and microbiology, specific gut microbiota profiles were positively associated with immune responsiveness, hinting that the gut-brain axis may profoundly impact cancer immunotherapy efficacy.

In the domain of survivorship, an important psychosocial study illuminated the role of self-advocacy in managing chronic pain among older breast cancer survivors. Research led by Karen E. Alsbrook involved a cohort of women aged 65 and above, analyzing their communication patterns, pain perception, and stigma surrounding opioid use. The findings highlighted that patients who actively engaged in self-advocacy perceived better communication with healthcare providers and experienced lower pain intensity. These insights emphasize the power of patient-centered care in mitigating the multifaceted burden of cancer-related pain, advocating for enhanced nurse-led interventions and education to empower this vulnerable population.

The robust scientific endeavors of MD Anderson Cancer Center were further recognized through prestigious honors awarded to distinguished faculty members. Notably, six professors, including Anirban Maitra and Scott Kopetz, were inducted into the Association of American Physicians, an honor reserved for visionary researchers who have significantly advanced medical science. Additionally, Ken Chen was elected a Fellow of the American Institute for Medical and Biological Engineering, reflecting his contributions to computational biology and bioinformatics critical to modern cancer genomics. Gabriel Hortobagyi received the European Society of Medical Oncology Breast Cancer Award, underscoring his leadership in breast cancer research.

Finally, luminaries such as Richard Gorlick and Michael Andreeff have been named to the Giants of Cancer Care class of 2025, solidifying their influence on pediatric and adult leukemia treatment innovations worldwide. These collective accolades celebrate an institution at the forefront of translating scientific discovery into meaningful clinical improvements.

This comprehensive body of research exemplifies how cutting-edge methodologies—from spatial transcriptomics and high-dimensional imaging to targeted molecular inhibitors—are transforming the oncology landscape. Emphasizing the integration of tumor biology, immune dynamics, and patient-centered approaches, MD Anderson’s breakthroughs herald a new era where precision medicine and holistic care converge to improve outcomes and quality of life for cancer patients globally.

Subject of Research: Comprehensive advances in cancer biology, treatment strategies, and patient care across pancreatic cancer, lung cancer, lymphoma, leukemia, glioblastoma, and breast cancer survivorship.

Article Title: Revolutionizing Oncology: MD Anderson’s Breakthroughs in Cancer Research and Patient Care

News Publication Date: Not explicitly provided in the source content

Web References:

• https://www.mdanderson.org/newsroom/research-highlights.html
• https://www.mdanderson.org/newsroom/research-highlights/comprehensive-spatial-map-provides-insights-into-pancreatic-cancer-metastases.h00-159775656.html
• https://www.nature.com/articles/s41586-025-08927-x
• https://www.mdanderson.org/newsroom/research-highlights/mapping-changes-in-lung-precancer-reveals-tim-3-as-potential-intervention-target.h00-159776445.html
• https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00162-X
• https://www.mdanderson.org/newsroom/research-highlights/novel-combination-provides-more-effective-treatment-option-for-mantle-cell-lymphoma.h00-159776445.html
• https://ascopubs.org/doi/pdf/10.1200/JCO-25-00690
• https://www.mdanderson.org/newsroom/research-highlights/activating-leukemia-stem-cells-makes-chemotherapy-more-effective-in-AML.h00-159776445.html
• https://www.nature.com/articles/s41408-025-01266-0
• https://www.mdanderson.org/newsroom/research-highlights/study-identifies-potential-biomarker-for-treatment-response-in-glioblastoma.h00-159776445.html
• https://www.nature.com/articles/s41467-025-56930-7
• https://www.mdanderson.org/newsroom/research-highlights/self-advocacy-may-lead-to-less-pain-in-older-breast-cancer-survivors.h00-159776445.html
• https://www.ons.org/publications-research/onf/52/3/associations-among-self-advocacy-patient-centered-communication-pain

References: Provided within respective journal articles linked above.

Keywords: Cancer research, pancreatic cancer, lung cancer, mantle cell lymphoma, acute myeloid leukemia, glioblastoma, breast cancer, tumor microenvironment, immune checkpoint blockade, spatial transcriptomics, BTK inhibitors, EZH1/2 inhibition, patient self-advocacy, immune biomarkers, cancer genomics.